Evidence map›Paper›PMID 32758261›Full record

ArticleJournal of translational medicine2020

Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank.

Erik J Woods, Aubrey M Sherry, John R Woods, James W Hardin, Michael LaFontaine, Gerald Brandacher, Brian H Johnstone

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Erik J WoodsOssium Health, Inc., 5742 W. 74th St, Indianapolis, IN, 46278, USA. erik@ossiumhealth.com.
Aubrey M SherryOssium Health, Inc., 5742 W. 74th St, Indianapolis, IN, 46278, USA.
John R WoodsRichard M. Fairbanks School of Public Health, Indiana University, 1050 Wishard Blvd, Indianapolis, IN, 46202, USA.
James W HardinArnold School of Public Health, University of South Carolina, 921 Assembly St, Columbia, SC, 29208, USA.
Michael LaFontaineDepartment of Biomedical Sciences, College of Osteopathic Medicine, Marian University, 3200 Cold Spring Rd, Indianapolis, IN, 46222, USA.
Gerald BrandacherDepartment of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, 601 N. Caroline St, Baltimore, MD, 21231, USA.
Brian H JohnstoneOssium Health, Inc., 5742 W. 74th St, Indianapolis, IN, 46278, USA.
Marian University - Indiana · USIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineJohns Hopkins Medicine · USUniversity of South Carolina · US

Funding

Deceased Donor Bone Marrow Salvage and ProcessingR43AI129444 · NIAID · OSSIUM HEALTH, INC. · PI WOODS, ERIK J. · 2017 to 2017
$273k
National Institute of Allergy and Infectious Diseases 1R43AI129444-01A1NIAID NIH HHS R43 AI129444
6 · The paper itself

Abstract

backgroundDeceased organ donors represent an untapped source of therapeutic bone marrow (BM) that can be recovered in 3-5 times the volume of that obtained from living donors, tested for quality, cryopreserved, and banked indefinitely for future on-demand use. A challenge for a future BM banking system will be to manage the prolonged ischemia times that are inevitable when bones procured at geographically-dispersed locations are shipped to distant facilities for processing. Our objectives were to: (a) quantify, under realistic field conditions, the relationship between ischemia time and the quality of hematopoietic stem and progenitor cells (HSPCs) derived from deceased-donor BM; (b) identify ischemia-time boundaries beyond which HSPC quality is adversely affected; (c) investigate whole-body cooling as a strategy for preserving cell quality; and (d) investigate processing experience as a variable affecting quality.

methodsSeventy-five bones from 62 donors were analyzed for CD34+ viability following their exposure to various periods of warm-ischemia time (WIT), cold-ischemia time (CIT), and body-cooling time (BCT). Regression models were developed to quantify the independent associations of WIT, CIT, and BCT, with the viability and function of recovered HSPCs.

resultsResults demonstrate that under "real-world" scenarios: (a) combinations of warm- and cold-ischemia times favorable to the recovery of high-quality HSPCs are achievable (e.g., CD34+ cell viabilities in the range of 80-90% were commonly observed); (b) body cooling prior to bone recovery is detrimental to cell viability (e.g., CD34+ viability < 73% with, vs. > 89% without body cooling); (c) vertebral bodies (VBs) are a superior source of HSPCs compared to ilia (IL) (e.g., %CD34+ viability > 80% when VBs were the source, vs. < 74% when IL were the source); and (d) processing experience is a critical variable affecting quality.

conclusionsOur models can be used by an emerging BM banking system to formulate ischemia-time tolerance limits and data-driven HSPC quality-acceptance standards.

Indexed as

Bone MarrowTissue DonorsAntigens, CD34Bone Marrow CellsBone Marrow TransplantationHematopoietic Stem CellsHumansIschemiaAntigens, CD34Bone marrow bankingBone marrow ischemia timeDeceased-donor bone marrowHematopoietic stem cell transplant

Identifiers

PMID32758261
PMCPMC7405448
OpenAlexW3047076812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.